# Progress Note 05 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN
- Date: 2026-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Whitley-Adeyemi, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Mrs. Lovelace is a 35-year-old mathematician with stage IVB adenocarcinoma of the cervix, on carboplatin, paclitaxel and pembrolizumab, who comes for a preventive visit. She had her third cycle a week ago. There has been no bleeding since the pelvic radiation. Her average pelvic pain is about 3 of 10 on long-acting morphine 15 mg twice a day, with one or two breakthrough doses on some days, and she is not drowsy in the mornings. Her bowels open every day or two since the laxatives were increased. She has mild tingling in her toes. She is working on her mathematics most mornings. She would like her vaccinations brought up to date while she is on treatment, and to set down her wishes. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 35 |
| Treatment | Three cycles of carboplatin, paclitaxel and pembrolizumab |
| Pain | About 3 of 10 on long-acting morphine; no morning drowsiness |
| Bowels | Opening every day or two |
| Mood | PHQ-2 2 |

## Health risk assessment

Completed by the patient on paper in the waiting room and reviewed with her face to face by Dr. Whitley-Adeyemi. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair; better than in the spring |
| Psychosocial | Worried about her debts and about her family; supported at home |
| Tobacco | Never |
| Alcohol | None since diagnosis; AUDIT-C 0 |
| Gambling | Has stopped betting since her diagnosis; would like help with the debts |
| Physical activity | Short walks most days |
| Nutrition | Appetite fair; weight steady |
| Sleep | Seven hours, broken on the nights after chemotherapy |
| Safety | Feels safe at home; morphine kept in a locked box; naloxone at home |
| Sexual health | Not sexually active since the bleeding began |
| Activities of daily living | Independent |
| Hearing and vision | No concerns |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tiredness for a few days after each cycle; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No mouth ulcers |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Bowels regular on laxatives; mild nausea for two days after each cycle |
| Genitourinary | Negative | No vaginal bleeding since radiation; light discharge; no urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Positive | Hair thinning on chemotherapy; no rash |
| Neurological | Positive | Mild tingling in the toes, not affecting walking |
| Endocrine | Negative | No heat or cold intolerance |
| Psychiatric | Negative | Mood fair; PHQ-2 score 2 |

12 systems reviewed. **S**

## Current medications

- Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain **S**
- Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole **S**
- Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 **S**
- Senna 8.6 mg tablet, two tablets by mouth at night **S**
- Polyethylene glycol 3350, 17 g in water by mouth once or twice a day **S**
- Acetaminophen 500 mg tablet, two tablets by mouth three times a day **S**
- Pembrolizumab 200 mg intravenously every 3 weeks **S**
- Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles **S**
- Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication **S**
- Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 53.6 kg; BMI 19.7 kg/m². All vital signs are synthetic.

PHQ-2: 2. All results are synthetic.

## Immunizations given today

- Pneumococcal conjugate vaccine (PCV20) **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tdap vaccine **S**
- Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Slender, alert; weight 53.6 kg, BMI 19.7; blood pressure 110/70, pulse 80 |
| Mouth | No mucositis or thrush |
| Neck | No thyroid enlargement; no lymph node enlargement |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft; mild suprapubic tenderness; no masses |
| Skin | Diffuse hair thinning; no rash |
| Neurological | Light touch slightly reduced at the toes; vibration normal; gait normal |
| Psychiatric | Engaged and humorous; not sedated |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan made for an adult on chemotherapy and immunotherapy. Inactivated vaccines are given between cycles: PCV20, the first recombinant zoster dose, Tdap, and the first hepatitis B dose. Live vaccines are not given. Cervical screening does not apply; breast cancer screening is not yet due. **S**
   - Second zoster dose in one to two months and second hepatitis B dose in one to two months, at the twenty-week visit.
   - Influenza and COVID-19 vaccines when the autumn vaccines are available.
   - Annual preventive visit in one year.
2. **Cancer-related pelvic pain** (G89.3). Controlled at about 3 of 10 on long-acting morphine without sedation. **S**
   - Continue the current doses; review at the fourteen-week visit.
3. **Long-term opioid therapy** (Z79.891). Taking morphine as prescribed from one prescriber; locked storage; naloxone at home. **S**
   - Continue the safety plan.
4. **Gambling debts**. She has stopped betting and feels ashamed of the debts; the stress of them affects her sleep. **S**
   - A social worker for debt advice; problem gambling support offered and accepted.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 110/70 mmHg |
| Depression screening | Completed today | PHQ-2 score 2; PHQ-9 9 five weeks ago |
| Tobacco use | Completed today | Never used tobacco |
| Unhealthy alcohol use | Completed today | AUDIT-C 0; no alcohol since diagnosis |
| Intimate partner violence screening | Completed today | Screened in private; negative |
| HIV screening | Up to date | Nonreactive at diagnosis |
| Hepatitis C screening | Up to date | Antibody nonreactive at diagnosis |
| Hepatitis B screening and vaccination | Completed today | Surface antigen, core antibody and surface antibody all negative before treatment; CpG-adjuvanted vaccine dose 1 of 2 today |
| Pneumococcal vaccine | Completed today | PCV20 today for an immunocompromising condition |
| Zoster vaccine | Completed today | Recombinant zoster vaccine dose 1 of 2 today, recommended from 19 for immunocompromised adults |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today |
| Influenza vaccine | Due | Inactivated vaccine in the autumn, between cycles |
| COVID-19 vaccine | Due | Current vaccine in the autumn; recommended for immunocompromised adults |
| HPV vaccine | Not indicated | Age 35 and already diagnosed with an HPV-related cancer |
| Live vaccines | Not indicated | Contraindicated during chemotherapy and immunotherapy |
| Cervical cancer screening | Not indicated | Under treatment for cervical cancer |
| Breast cancer screening | Not indicated | Not due before 40 at average risk |
| Diabetes and lipid screening | Not indicated | Not a priority during treatment; BMI 19.7 |
| Contraception and pregnancy | Completed today | Not sexually active; told that chemotherapy and pembrolizumab can harm a pregnancy and to use contraception if that changes |

## Advance care planning

Voluntary advance care planning discussion of about 30 minutes, with her consent, in the context of metastatic cancer. She named a health care agent and an alternate, recorded in the chart and not named here, and completed a health care proxy form. She wants treatment aimed at living longer while it lets her think and work, wants to be told the truth about her illness directly, and does not want her life prolonged by machines if she could no longer think clearly. Her wishes on resuscitation will be revisited after the restaging scan. A copy was sent to her oncology and palliative care teams. **S**

## Guideline basis

- Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024), American Society of Clinical Oncology
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Fourteen-week review in three weeks, after the restaging CT. **S**
- Next scheduled visit 2026-09-08: fourteen-week review: restaging CT, blood counts, iron and thyroid, pain, and a goals-of-care conversation. **S**
